Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

447 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Implementation of a Community-Based Triage for Patients with Suspected Transient Ischemic Attack or Minor Stroke Study: A Prospective Multicenter Observational Study.
Taguchi H, Hasegawa Y, Bandoh K, Koyasu H, Watanabe Y, Yamashita K, Shimazaki K, Shima H, Miyakawa M, Niwa Y; COMBAT-TIA Study Investigators. Taguchi H, et al. Among authors: miyakawa m. J Stroke Cerebrovasc Dis. 2016 Apr;25(4):745-51. doi: 10.1016/j.jstrokecerebrovasdis.2015.11.013. Epub 2016 Jan 13. J Stroke Cerebrovasc Dis. 2016. PMID: 26775272
Effects of ipragliflozin on the development and progression of kidney disease in patients with type 2 diabetes: An analysis from a multicenter prospective intervention study.
Matsuba I, Kawata T, Iemitsu K, Asakura T, Amemiya H, Ishikawa M, Ito S, Kaneshiro M, Kanamori A, Kubota A, Shinoda K, Takai M, Takuma T, Takihata M, Takeda H, Tanaka K, Matsuzawa Y, Machimura H, Minagawa F, Minami N, Mokubo A, Miyakawa M, Terauchi Y, Tanaka Y. Matsuba I, et al. Among authors: miyakawa m. J Diabetes Investig. 2020 Sep;11(5):1248-1257. doi: 10.1111/jdi.13248. Epub 2020 Apr 25. J Diabetes Investig. 2020. PMID: 32149469 Free PMC article.
Factors Predicting Therapeutic Efficacy of Combination Treatment With Sitagliptin and Insulin in Type 2 Diabetic Patients: The ASSIST-K Study.
Ishikawa M, Takai M, Maeda H, Kanamori A, Kubota A, Amemiya H, Iizuka T, Iemitsu K, Iwasaki T, Uehara G, Umezawa S, Obana M, Kaneshige H, Kaneshiro M, Kawata T, Sasai N, Saito T, Takuma T, Takeda H, Tanaka K, Tsurui N, Nakajima S, Hoshino K, Honda S, Machimura H, Matoba K, Minagawa F, Minami N, Miyairi Y, Mokubo A, Motomiya T, Waseda M, Miyakawa M, Naka Y, Terauchi Y, Tanaka Y, Matsuba I. Ishikawa M, et al. Among authors: miyakawa m. J Clin Med Res. 2015 Aug;7(8):607-12. doi: 10.14740/jocmr2149w. Epub 2015 Jun 9. J Clin Med Res. 2015. PMID: 26124906 Free PMC article.
Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study.
Iizuka T, Iemitsu K, Takihata M, Takai M, Nakajima S, Minami N, Umezawa S, Kanamori A, Takeda H, Kawata T, Ito S, Kikuchi T, Amemiya H, Kaneshiro M, Mokubo A, Takuma T, Machimura H, Tanaka K, Asakura T, Kubota A, Aoyagi S, Hoshino K, Ishikawa M, Matsuzawa Y, Obana M, Sasai N, Kaneshige H, Minagawa F, Saito T, Shinoda K, Miyakawa M, Tanaka Y, Terauchi Y, Matsuba I. Iizuka T, et al. Among authors: miyakawa m. J Clin Med Res. 2016 Feb;8(2):116-25. doi: 10.14740/jocmr2417w. Epub 2015 Dec 28. J Clin Med Res. 2016. PMID: 26767080 Free PMC article.
Correction: Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study.
Iizuka T, Iemitsu K, Takihata M, Takai M, Nakajima S, Minami N, Umezawa S, Kanamori A, Takeda H, Kawata T, Ito S, Kikuchi T, Amemiya H, Kaneshiro M, Mokubo A, Takuma T, Machimura H, Tanaka K, Asakura T, Kubota A, Aoyagi S, Hoshino K, Ishikawa M, Matsuzawa Y, Obana M, Sasai N, Kaneshige H, Minagawa F, Saito T, Shinoda K, Miyakawa M, Tanaka Y, Terauchi Y, Matsuba I. Iizuka T, et al. Among authors: miyakawa m. J Clin Med Res. 2016 Mar;8(3):267. doi: 10.14740/jocmr2417wc1. Epub 2016 Jan 26. J Clin Med Res. 2016. PMID: 26858805 Free PMC article.
Factors Influencing Changes in Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With Ipragliflozin: Interim Analysis of the ASSIGN-K Study.
Iemitsu K, Iizuka T, Takihata M, Takai M, Nakajima S, Minami N, Umezawa S, Kanamori A, Takeda H, Kawata T, Ito S, Kikuchi T, Amemiya H, Kaneshiro M, Mokubo A, Takuma T, Machimura H, Tanaka K, Asakura T, Kubota A, Aoyagi S, Hoshino K, Ishikawa M, Obana M, Sasai N, Kaneshige H, Miyakawa M, Tanaka Y, Terauchi Y, Matsuba I. Iemitsu K, et al. Among authors: miyakawa m. J Clin Med Res. 2016 May;8(5):373-8. doi: 10.14740/jocmr2492w. Epub 2016 Mar 20. J Clin Med Res. 2016. PMID: 27081422 Free PMC article.
Safety and efficacy of adding sitagliptin to insulin in patients with type 2 diabetes: the ASSIST-K study.
Takai M, Ishikawa M, Maeda H, Kanamori A, Kubota A, Amemiya H, Iizuka T, Iemitsu K, Iwasaki T, Uehara G, Umezawa S, Obana M, Kaneshige H, Kaneshiro M, Kawata T, Sasai N, Saito T, Takuma T, Takeda H, Tanaka K, Tsurui N, Nakajima S, Hoshino K, Honda S, Machimura H, Matoba K, Minagawa F, Minami N, Miyairi Y, Mokubo A, Motomiya T, Waseda M, Miyakawa M, Naka Y, Terauchi Y, Tanaka Y, Matsuba I. Takai M, et al. Among authors: miyakawa m. Diabetes Res Clin Pract. 2014 Mar;103(3):e30-3. doi: 10.1016/j.diabres.2013.12.045. Epub 2014 Jan 6. Diabetes Res Clin Pract. 2014. PMID: 24525293
Efficacy and Safety of Adding Sitagliptin in Type 2 Diabetes Patients on Insulin: Age-Stratified Comparison at One Year in the ASSIST-K Study.
Takai M, Ishikawa M, Maeda H, Kanamori A, Kubota A, Amemiya H, Iizuka T, Iemitsu K, Iwasaki T, Uehara G, Umezawa S, Obana M, Kaneshige H, Kaneshiro M, Kawata T, Sasai N, Saito T, Takuma T, Takeda H, Tanaka K, Nakajima S, Hoshino K, Honda S, Machimura H, Matoba K, Minagawa F, Minami N, Miyairi Y, Mokubo A, Motomiya T, Waseda M, Miyakawa M, Terauchi Y, Tanaka Y, Matsuba I. Takai M, et al. Among authors: miyakawa m. J Clin Med Res. 2019 May;11(5):311-320. doi: 10.14740/jocmr3677. Epub 2019 Apr 14. J Clin Med Res. 2019. PMID: 31019624 Free PMC article.
Effects of 1-year treatment with canagliflozin on body composition and total body water in patients with type 2 diabetes.
Matsuba I, Takihata M, Takai M, Maeda H, Kubota A, Iemitsu K, Umezawa S, Obana M, Kaneshiro M, Kawata T, Takuma T, Takeda H, Machimura H, Mokubo A, Motomiya T, Asakura T, Kikuchi T, Matsuzawa Y, Ito S, Miyakawa M, Terauchi Y, Kanamori A. Matsuba I, et al. Among authors: miyakawa m. Diabetes Obes Metab. 2021 Dec;23(12):2614-2622. doi: 10.1111/dom.14508. Epub 2021 Aug 12. Diabetes Obes Metab. 2021. PMID: 34338409
The Comparison of the Kidney Effects of Dipeptidyl Peptidase 4 Inhibitors and Glucagon-Like Peptide 1 Agonist-Administered Concomitant with Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Kobayashi K, Toyoda M, Hatori N, Sato K, Miyakawa M, Tamura K, Kanamori A. Kobayashi K, et al. Among authors: miyakawa m. J Diabetes Res. 2021 Dec 21;2021:6573369. doi: 10.1155/2021/6573369. eCollection 2021. J Diabetes Res. 2021. PMID: 35028319 Free PMC article.
447 results